Anupam Rasayan India Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported an 11% year-on-year increase in total income for Q2 FY27, reaching INR821 crore. EBITDA saw a substantial 41% growth to INR202 crore, with EBITDA margin improving to 25%. This performance reflects the impact of acquisitions like Bliss GVS Pharma and strategic growth initiatives.
Anupam Rasayan Reports Strong Q2 and H1 FY27 Financials
Anupam Rasayan India Limited has announced its unaudited financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2027, ending September 30, 2026. The company demonstrated robust performance, highlighted by significant growth in revenue and profitability.
Q2 FY27 Performance
For the second quarter of FY27, Anupam Rasayan’s total income stood at INR821 crore, an 11% increase compared to INR739 crore in the corresponding quarter of the previous year. The company’s EBITDA for the quarter grew by 41% year-on-year to INR202 crore, with the EBITDA margin improving to approximately 25% from 19.4% in Q2 FY26. Profit After Tax (PAT) for the quarter was INR65 crore, a 14% growth year-on-year.
H1 FY27 Performance
In the first half of FY27, the consolidated total income reached INR1,489 crore, marking a strong 21% year-on-year growth from INR1,230 crore in H1 FY26. EBITDA for H1 FY27 was INR377 crore, an increase of 38% from INR273 crore in H1 FY26. The EBITDA margin for the half-year improved to 25.5% from 22.2% in the prior year. PAT for H1 FY27 was INR116 crore, up 10% year-on-year.
Strategic Acquisitions and Business Segments
The quarter was marked by the completion of the acquisition of Bliss GVS Pharma Limited, a significant milestone towards building an integrated global pharmaceutical platform. This acquisition is expected to enhance the company’s capabilities in finished dosage formulations and expand its presence in regulated markets.
The revenue breakup for Q2 FY27 highlights the diversified business mix: Life science-related specialty chemicals contributed 42%, Performance Materials contributed 28%, and other fluorinated products contributed 29%.
Outlook and Growth Strategy
Anupam Rasayan is focusing on strengthening its product portfolio, accelerating commercialization, integrating recent acquisitions, and expanding its global customer relationships. The company aims to leverage its chemistry platform, technology capabilities, and manufacturing footprint for future growth. Long-term customer relationships and contracts now stand at approximately INR17,496 crore, providing significant revenue visibility over multiple years.
Source: BSE
